PART I Item 1. Bus iness Overview We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. We were founded in April 2010 by our President and Chief Exe...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-18 | 2025-12-31 | 0001193125-26-057329 | EDGAR | 85K words |
| 2025-02-19 | 2024-12-31 | 0000950170-25-023312 | EDGAR | — |
| 2024-02-21 | 2023-12-31 | 0000950170-24-017879 | EDGAR | — |
| 2023-02-17 | 2022-12-31 | 0000950170-23-003096 | EDGAR | — |
| 2022-02-15 | 2021-12-31 | 0000950170-22-001284 | EDGAR | — |
| 2021-02-12 | 2020-12-31 | 0001564590-21-005610 | EDGAR | — |
| 2020-02-14 | 2019-12-31 | 0001564590-20-004667 | EDGAR | — |
| 2019-02-20 | 2018-12-31 | 0001564590-19-003324 | EDGAR | — |
| 2018-02-21 | 2017-12-31 | 0001564590-18-002535 | EDGAR | — |
| 2017-02-17 | 2016-12-31 | 0001564590-17-001714 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-265126 | EDGAR | 55K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-103290 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-064726 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-121679 | EDGAR | — |
| 2024-08-02 | 2024-06-30 | 0000950170-24-089488 | EDGAR | — |
| 2024-05-03 | 2024-03-31 | 0000950170-24-052346 | EDGAR | — |
| 2023-11-03 | 2023-09-30 | 0000950170-23-058427 | EDGAR | — |
| 2023-08-04 | 2023-06-30 | 0000950170-23-038173 | EDGAR | — |
| 2023-05-05 | 2023-03-31 | 0000950170-23-018017 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021366 | EDGAR | — |
| 2022-07-29 | 2022-06-30 | 0000950170-22-013411 | EDGAR | — |
| 2022-05-06 | 2022-03-31 | 0000950170-22-007940 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001193125-26-139084 | EDGAR | 1K words |
| 2026-03-30 | 0001193125-26-130498 | EDGAR | — |
| 2026-03-12 | 0001193125-26-103167 | EDGAR | — |
| 2026-02-23 | 0001193125-26-062568 | EDGAR | — |
| 2026-02-12 | 0001193125-26-048738 | EDGAR | — |
| 2026-02-03 | 0001193125-26-034474 | EDGAR | — |
| 2026-01-30 | 0001193125-26-030590 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009791 | EDGAR | — |
| 2025-12-30 | 0001193125-25-337099 | EDGAR | — |
| 2025-12-29 | 0001193125-25-332422 | EDGAR | — |
266 total filings indexed. 234 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001515673 |
| Ticker | RARE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ultragenyx.com |
| Listed | 2014-01-31 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report